Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Globe Newswire (Thu, 16-Jul 3:36 AM ET)
Solaris Energy Infrastructure Set to Join S&P SmallCap 600
PRNewswire (Thu, 9-Jul 5:48 PM ET)
Globe Newswire (Tue, 30-Jun 8:03 AM ET)
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 25-Jun 1:57 PM ET)
Business Wire (Wed, 24-Jun 2:38 PM ET)
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 19-May 6:22 PM ET)
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 12-May 2:56 AM ET)
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Globe Newswire (Mon, 11-May 4:12 PM ET)
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 8-May 5:56 PM ET)
Market Chameleon (Thu, 7-May 3:20 AM ET)
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Catalyst Pharmaceuticals trades on the NASDAQ stock market under the symbol CPRX.
As of July 17, 2026, CPRX stock price was flat at $31.49 with million shares trading.
CPRX has a beta of 0.41, meaning it tends to be less sensitive to market movements. CPRX has a correlation of 0.05 to the broad based SPY ETF.
CPRX has a market cap of $3.85 billion. This is considered a Mid Cap stock.
Last quarter Catalyst Pharmaceuticals reported $149 million in Revenue and $.79 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.16.
In the last 3 years, CPRX traded as high as $32.56 and as low as $11.55.
The top ETF exchange traded funds that CPRX belongs to (by Net Assets): VTI, VXF, VTWO, VIOO, DFMC.
CPRX has outperformed the market in the last year with a price return of +48.7% while the SPY ETF gained +20.4%. CPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.6% and +0.1%, respectively, while the SPY returned +6.3% and -0.1%, respectively.
CPRX support price is $31.46 and resistance is $31.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPRX shares will trade within this expected range on the day.